GTC Biotherapeutics (fka GTCB)

[alia]

agree, however, at times it is difficult convincing pharmaceutial companies who have been living and breathing a product for years and agree by common consensus that it is safer that the data to say so convincingly does not always exist.
I also think it is important in this case to gain market share and get post marketing safety data for the product, so you can say (hopefully), hey, look, it is really safer
p.s. how the plasma guys respond to lower priced atryn will be interesting...i can see a pr war on the basis of the nasty, genetically engineered goats ( and perhaps for this reason, it is also good to have the French plasma guys on board, France being another huge market...)